Articles & insights
HCP Engagement & Transparency Reporting
Fair market value, transfers of value and disclosure under EFPIA and national transparency laws.
Managing Healthcare Professionals’ Personal Data under GDPR: CRM, FMV and Engagement Records
Apply GDPR to HCP engagement data in pharma: purpose, lawful basis, data minimisation in FMV, accuracy, processors, transfers and retention.
Read the article 2026-09-29GDPR and Transparency Reporting: Disclosing HCP Transfers of Value
How GDPR applies to disclosing HCP transfers of value: consent or legitimate interests, privacy information, objections, accuracy and processor controls.
Read the article 2026-07-17Top Transparency Reporting Mistakes Pharmaceutical Companies Should Avoid
Six transparency reporting mistakes in pharma, from year-end-only data collection to misclassified transfers of value, and how to avoid them.
Read the article 2026-02-23Sunshine Act in France: Understanding the Transparency in Healthcare System
The French Sunshine Act (Loi Bertrand) explained: who must report, what is published on Transparence Santé, timelines, penalties and EFPIA differences.
Read the article 2026-02-16Transparency Reporting in the Pharmaceutical Industry: Legal Compliance Versus Ethical Responsibility
Transparency reporting in pharma beyond legal compliance: sunshine laws, self-regulation, and why disclosure must reflect ethical responsibility.
Read the article 2026-02-03Fair Market Value (FMV) in Healthcare Compliance: Turning Regulatory Expectation into an Operational Capability
Fair market value (FMV) for HCP compensation: why it faces heightened scrutiny, its role in ABAC and transparency, and how to make it defensible.
Read the article 2025-10-24Staying Ahead of the Curve: Audit-Readiness Best Practices Across European Life Sciences Markets
Audit-readiness best practices for European life sciences: harmonised SOPs, real-time monitoring, consistent FMV frameworks and proactive training.
Read the article 2025-09-16How to Avoid Common Healthcare Compliance Mistakes in Pharmaceuticals
Six common pharma compliance mistakes, from unbalanced materials and unjustified hospitality to weak third-party oversight, and how to prevent them.
Read the article 2025-06-12Stakeholder Engagement vs Risk: EFPIA & IFPMA Compliance
Balancing HCP and patient organisation engagement with EFPIA and IFPMA compliance: real-world dilemmas on hospitality and sponsorship.
Read the articleQuestions, answered
HCP Engagement & Transparency Reporting: common questions
Where are UK industry payments to HCPs and HCOs published?
On Disclosure UK, the ABPI’s database, which is part of a Europe-wide initiative to increase transparency between pharmaceutical companies and healthcare professionals and organisations.
How is transparency handled in France?
France has a legal transparency regime under Loi n° 2011-2012 (the Loi Bertrand). Disclosures are published on the public Transparence Santé database, managed by the Direction générale de la santé.